Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Forget Novo Nordisk. Pfizer's Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait
01:55pm, Tuesday, 23'rd Jun 2026
Everyone is still arguing about Novo Nordisk (NYSE:NVO | NVO Price Prediction), the Danish obesity juggernaut whose
NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research Push
12:11pm, Tuesday, 23'rd Jun 2026
Novo Nordisk stock rises 6% after the launch of a EUR 60.2M foundation-backed initiative to speed cardiometabolic drug discovery and support Europe-wide innovation.
Novo Nordisk: The Selloff Looks Like A Gift, And I'm Buying
08:54am, Tuesday, 23'rd Jun 2026
Novo Nordisk is upgraded to a 'Strong Buy' after a weak Q1 and significant stock price decline, presenting a compelling long-term entry point. NVO's GLP-1 portfolio, including Wegovy and Ozempic, face
Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk
08:15pm, Monday, 22'nd Jun 2026
Viking Therapeutics has a weight-loss program that looks to be competitive with medicines already on the market. It's unclear how its candidate compares to competing programs that are still in clinica
A Look at Novo Nordisk AS (NVO) After 6.2% Gain -- GF Value $144.58 vs Price $45.88
05:15pm, Monday, 22'nd Jun 2026
On June 22, 2026, Novo Nordisk AS (NVO) shares rose 6.2% to a current price of $45.88. The stock has experienced a volatile year, with a 52-week high of $74.38
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
10:39am, Monday, 22'nd Jun 2026
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.
Novo Nordisk's Wegovy pill headlines mask complicated competitive reality
08:43am, Monday, 22'nd Jun 2026
Novo Nordisk's (NYSE:NVO) Wegovy pill is running three times ahead of rival Zepbound at the equivalent stage of launch, according to pharmacy data, a headline that implies dominant market positioning
Novo Nordisk Owner Commits $69 Million to Europe Biotech Incubators
08:28am, Monday, 22'nd Jun 2026
Novo Nordisk Foundation, the primary owner of Novo Nordisk (NVO), is launching a new European incubator network as obesity and diabetes drug research continues
South Africa court bars iDexis from selling compounded Ozempic in Novo Nordisk case
06:42am, Monday, 22'nd Jun 2026
South Africa's High Court has granted Novo Nordisk an interim interdict barring a local pharmacy group from manufacturing and selling compounded weight-loss medicines containing semaglutid
Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?
12:15pm, Saturday, 20'th Jun 2026
Novo Nordisk was the first to market with a GLP-1 weight-loss drug. It lost its early lead to Eli Lilly, which is now the name to beat in the GLP-1 race.
Novo Nordisk Stock Rally as Owner Unveils $69 Million Obesity Research Push
01:01pm, Friday, 19'th Jun 2026
Novo Nordisk (NVO) shares in Copenhagen rose about 5% on Friday after its majority owner, the Novo Nordisk Foundation, launched CardioMetabolic Bridge, a pan-Eu
Novo Nordisk faces limited upside from ZEUS trial as patent cliff looms, Deutsche Bank warns
09:32am, Friday, 19'th Jun 2026
Deutsche Bank expects Novo Nordisk's (NYSE:NVO) pending ZEUS trial to miss, but sees limited upside even if the drug proves successful, given the company's...
Novo Nordisk faces limited upside from ZEUS trial as patent cliff looms, Deutsche Bank warns
08:37am, Friday, 19'th Jun 2026
Deutsche Bank expects Novo Nordisk's (NYSE:NVO) pending ZEUS trial to miss, but sees limited upside even if the drug proves successful, given the company's looming patent cliff. The analyst has set a
Can Wegovy Pill's Europe Push Help NVO Offset Mounting Pressures?
11:06am, Thursday, 18'th Jun 2026
Wegovy pill's U.K. approval gives Novo Nordisk its first European launch path ahead of wider EU approval as it seeks growth amid mounting pricing and competitive pressures.
My Top 5 Dividend Picks For June
04:40am, Thursday, 18'th Jun 2026
Keurig Dr Pepper, Novo Nordisk, Sonoco Products, Domino's Pizza, and Realty Income are top June dividend picks, all rated Buy or Strong Buy. KDP, NVO, SON, DPZ, and O are each trading 15–37% below e
